Abstract:Objective: To explore the serum cyclic polypeptide biomarkers for ovarian cancer diagnosis. Methods: A total of 54 patients with epithelial ovarian cancer confirmed by pathology in Cancer Hospital, Chinese Academy of Medical Sciences from March 2018 to September 2018 were selected as the study subjects, and 40 healthy women with normal examination results in the cancer screening center were selected as the control. All of the samples were randomly divided into training set and validation set at the ratio of 1∶1 with a random number. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) combined with magnetic bead technology was used for detecting peptide profiling in serum samples to screen significantly differently expressed peptides between ovarian cancer group and control group of the training set (score>5). Receiver operating characteristic (ROC) curve analysis was used to screen differential peptide peaks with area under curve (AUC) ≥0.8, sensitivity and specificity>90% in the training set and validation set. Liquid chromatography-mass spectrometry (LC-MS/MS) was further used to determine the composition of differentially expressed peptides. Results: By comparing the peptide profiles of the two groups, 102 differential peptide peaks were initially detected in the mass-to-charge ratio range of 1 000 to 10 000. ROC curve analysis showed that there were 42 differential peptide peaks with AUC ≥0.8 in both training set and validation set, 19 of which were highly expressed in ovarian cancer group, and 23 were lowly expressed. There were 15 different peptide peaks in highly expressed ovarian cancer group with sensitivity and specificity over 90%. The mass-to-charge ratios were 7 744.27, 5 913.41, 5 329.87, 4 634.21, 4 202.02, 3 879.26, 3 273.35, 3 253.79, 3 234.34, 2 950.33, 2 664.51, 2 018.38, 1 893.37, 1 498.69 and 1 287.55. There were 15 different peptide peaks in lowly expressed ovarian cancer group with sensitivity and specificity over 90%, the mass-to-charge ratios were 9 288.46, 7 759.77, 5 925.24, 4 652.77, 4 210.42, 3 887.02, 3 279.90, 3 240.82, 2 962.15, 2 932.70, 2 022.42, 1 897.16, 1 501.69, 1 337.38 and 1 290.13. No protein composition was identified in 15 different peptide peaks in lowly expressed ovarian cancer group. The two protein compositions identified in 15 different peptide peaks in highly expressed ovarian cancer group were recombinant serglycin (SRGN) and fibinogen alpha chain (FGA), the mass-to-charge ratios of which were 1 498.696 and 5 913.417, respectively. The sensitivity and specificity of the two proteins for ovarian cancer diagnosis were 100%, 100% and 90.9%, 100%, respectively. Conclusion: SRGN and FGA are highly expressed in the serum of ovarian cancer patients, which may be potential diagnostic markers for ovarian cancer.

Proteomic markers for early detection of ovarian cancer

Identification of Serum Biomarkers for Ovarian Cancer Using MALDI–TOF-MS Combined with Magnetic Beads

Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.

Proteomic profiling of ovarian cancer in serum using magnetic bead based sample fractionation and MALDI-TOF MS

Proteomic Studies of Early-Stage and Advanced Ovarian Cancer Patients.

Alterations in the serum proteome profile during the development of ovarian cancer

A Multiplex Methylation-Specific Pcr Assay For Detection Of Early-Stage Ovarian Cancer Using Cell-Free Serum Dna

Proteomic Pattern Established with Advanced Ovarian Cancer Be Used in Diagnosis of Early-Stage Ovarian Cancer

Tumor markers for early detection of ovarian cancer

Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics

[Identification of Serum Peptide Biomarker for Ovarian Cancer Diagnosis by Clin-TOF-II-MS Combined with Magnetic Beads Technology].

A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.

An Integrated Approach Utilizing Proteomics and Bioinformatics to Detect Ovarian Cancer

Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses

Clinical potential of proteomics in the diagnosis of ovarian cancer

Screening Ovarian Cancers with Raman Spectroscopy of Blood Plasma Coupled with Machine Learning Data Processing.

Advances in tumor markers of ovarian cancer for early diagnosis

Identification and validation of differential plasma diagnostic biomarkers of ovarian cancer based on lipidomics

Untargeted Metabolomic Characterization of Ovarian Tumors

[Study for Drug-Resistance of Epithelial Ovarian Cancer by Serum Protein Profiling].

Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers